<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003159" GROUP_ID="DEMENTIA" ID="530500012312084525" MERGED_FROM="" MODIFIED="2008-11-05 17:40:02 +0100" MODIFIED_BY="Helen Collins" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2008-11-05 17:40:02 +0100" MODIFIED_BY="Helen Collins">
<TITLE>Nicergoline for dementia and other age associated forms of cognitive impairment</TITLE>
<CONTACT MODIFIED="2008-11-05 17:40:02 +0100" MODIFIED_BY="Helen Collins"><PERSON ID="6233" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Mario</FIRST_NAME><LAST_NAME>Fioravanti</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Professor of Clinical Psychology</POSITION><EMAIL_1>mario.fioravanti@uniroma1.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatric Science and Psychological Medicine</DEPARTMENT><ORGANISATION>University of Rome "La Sapienza"</ORGANISATION><ADDRESS_1>P.le A. Moro, 5</ADDRESS_1><CITY>Rome</CITY><ZIP>00185</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+3906 4991 ext: 2287</PHONE_1><PHONE_2>+3906 4451.622</PHONE_2><FAX_1>+3906 4451.622</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-05 17:40:02 +0100" MODIFIED_BY="Helen Collins"><PERSON ID="6233" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Mario</FIRST_NAME><LAST_NAME>Fioravanti</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Professor of Clinical Psychology</POSITION><EMAIL_1>mario.fioravanti@uniroma1.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatric Science and Psychological Medicine</DEPARTMENT><ORGANISATION>University of Rome "La Sapienza"</ORGANISATION><ADDRESS_1>P.le A. Moro, 5</ADDRESS_1><CITY>Rome</CITY><ZIP>00185</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+3906 4991 ext: 2287</PHONE_1><PHONE_2>+3906 4451.622</PHONE_2><FAX_1>+3906 4451.622</FAX_1></ADDRESS></PERSON><PERSON ID="4621" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Leon</FIRST_NAME><LAST_NAME>Flicker</LAST_NAME><POSITION>Professor of Geriatric Medicine</POSITION><EMAIL_1>leonflic@cyllene.uwa.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Western Australian Centre for Health &amp; Ageing - WACHA</DEPARTMENT><ORGANISATION>University of Western Australia</ORGANISATION><ADDRESS_1>Royal Perth Hospital</ADDRESS_1><ADDRESS_2>Box X2213</ADDRESS_2><CITY>Perth</CITY><ZIP>6847</ZIP><REGION>Western Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>618 9224 3992</PHONE_1><PHONE_2>618 9224 2750</PHONE_2><FAX_1>618 9224 2063</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-05 16:36:05 +0000" MODIFIED_BY="Helen Collins">
<UP_TO_DATE>
<DATE DAY="24" MONTH="8" YEAR="2001"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="5" YEAR="2001"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="6" YEAR="2003"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2001"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="5" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="24" MONTH="8" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-05 16:36:46 +0000" MODIFIED_BY="Helen Collins">
<SUMMARY MODIFIED="2008-11-05 16:36:46 +0000" MODIFIED_BY="Helen Collins">
<TITLE MODIFIED="2008-11-05 16:36:44 +0000" MODIFIED_BY="Helen Collins">Nicergoline may improve cognition and behavioural function of people with mild to moderate dementia</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-05 16:36:46 +0000" MODIFIED_BY="Helen Collins">
<P>Nicergoline is an ergot derivative which has been registered in over 50 countries and has been used for more than three decades for the treatment of cognitive, affective, and behavioural disorders of older people. During the time it has been in use, the rationale for its clinical use has evolved. Initially regarded as a vasoactive drug, it was mainly prescribed for cerebrovascular disorders. Since then, findings suggesting a more complex pharmacological profile of nicergoline have led to its being considered for the treatment of other forms of dementia, including Alzheimer's Disease. There is some evidence of positive effects of nicergoline on cognition and behaviour and these effects are supported by an effect on clinical global impression.There was some evidence that there was increased risk of adverse effects associated with nicergoline. This drug has not been evaluated using current diagnostic categories such as MCI or in association with therapeutic agents of different nature such as cholinesterase or antioxidant drugs.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-05 16:36:36 +0000" MODIFIED_BY="Helen Collins">
<ABS_BACKGROUND>
<P>Nicergoline is an ergot derivative currently in use in over fifty countries for more than three decades, for the treatment of cognitive, affective, and behavioral disorders of older people. It was initially considered as a vasoactive drug and mainly prescribed for cerebrovascular disorders. Recent findings suggest other actions which has provided a rationale for the use of nicergoline for the treatment of various forms of dementia, including Alzheimer's Disease. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine whether there is evidence of efficacy of nicergoline in the treatment of dementia and other age-associated forms of cognitive decline,and to assess the safety and tolerability of the drug. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>1. Electronic databases search. The Cochrane Controlled Trials Register (which contains citations from the MEDLINE, EMBASE, Psych LIT, and hand searches of geriatric, dementia, psychogeriatric journals, and conference abstracts) was searched using the following terms: 'Nicergoline', 'Sermion'. <BR/>2. Reference search. The reference lists of all obtained studies was checked. <BR/>3. Pharmaceutical company Pharmacia &amp; Upjohn, owners of the rights to produce and market nicergoline in various different countries, was asked to provide data and reports of clinical trials. In case of unavailability of numerical data in published studies, the authors of each paper, were asked for any published or unpublished data. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>- All unconfounded, double-blind, randomized, placebo-controlled, published and unpublished trials were sought. Non-randomized trials were excluded. Open trials were considered for inclusion if patients were randomized to the different treatment groups. <BR/>- All patients diagnosed as having dementia or other cognitive disorder defined according to classification criteria accepted at the time of each study. <BR/>- Nicergoline given at any dose for more than one day with placebo control.</P>
<P>Type of outcome variables: </P>
<P>1. Cognitive function (as measured by psychometric tests). <BR/>2. Clinical impression (such as CIBIC or other clinical global measures of change). <BR/>3. Functional performance including dependency. <BR/>4. Behavioural disturbance. <BR/>5. Safety and acceptability as measured by the incidence of adverse effects (including side-effects) leading to withdrawal. <BR/>6. Death <BR/>7. Effect on carer <BR/>8. Use of services <BR/>9. Quality of life. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>A comprehensive search of the international literature and the producing company archives has been performed to identify all possible sources of data for this review. Only those trials fulfilling the inclusion criteria of belonging to either category A or B of allocation concealment, as defined by the Cochrane Organisation, were examined for data extraction by one reviewer. If there was doubt then the other reviewer was consulted. Data availability restricted analyses to 'completers' analyses for the outcome measures. Outcomes able to be assessed included: Behaviour, Cognition, Clinical Judgment, Tolerability, EEG.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-05 16:36:36 +0000" MODIFIED_BY="Helen Collins">
<P>The Sandoz Clinical Assessment Geriatric Scale (SCAG) was the outcome used in the largest number of patients (814 patients). The results from these studies were homogeneous in nature despite including patients observed for periods of time ranging from 2 months to 12 months. There was a difference in favour of the active treatment in reducing the behavioural symptoms described by this scale, -5.18 points [-8.03, -2.33]. This scale has a maximum of 133 points. The therapeutic effects of nicergoline seem to be evident by 2 months of treatment and maintained for 6 months. In general other behavioural outcome measures which include the GRS, the IADL, and the MACC and were episodically used in few studies, failed to demonstrate statistically significant results although there was a trend favouring treatment.<BR/>Cognitive assessment has been performed in a moderate number of patients with the MMSE (261 patients) and the ADAS-Cog (342 patients). No significant heterogeneity was found for these trials, despite the trials extending over periods of treatment of 3 to 12 months. There was a difference between treatment and control groups on the MMSE favouring nicergoline treatment. At 12 months the effect size was 2.86 [0.98, 4.74] The effect size for the ADAS-Cog, used exclusively with Alzheimer's disease patients, did not reveal a significant benefit. At 12 months the trend favoured treatment (-1.64 [-4.62, 1.34]). The other results from various cognitive measures tended to favour nicergoline but this was based on a small number of cases.<BR/>The clinical impression of change obtained from a total of 921 patients was homogeneous across the studies, despite reflecting changes over periods of time ranging from 2 to 12 months. The Peto odd ratio for improvement in the subjects treated with nicergoline over these varying time periods was 3.33 [2.50, 4.43].<BR/>Tolerability assessed in 1427 patients was homogeneous across all studies and demonstrated a mildly increased risk of adverse events on treatment, OR 1.51[1.10, 2.07].</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The clinical studies on nicergoline were carried out with diverse criteria and modalities of evaluation. Despite this, the 14 studies included in this review, have presented generally consistent results. Results of this meta-analysis provide some evidence of positive effects of nicergoline on cognition and behaviour and these effects are supported by an effect on clinical global impression. There was some evidence that there were increased risk of adverse effects associated with nicergoline. These results were obtained on older patients with mild to moderate cognitive and behavioural impairment of various clinical origins, including chronic cerebrovascular disorders and Alzheimer's dementia. The few studies specifically performed on patients with Alzheimer's disease were performed with too few people to give a definitive answer to the questions concerning the use of nicergoline for this form of dementia.<BR/>This drug has not been evaluated using current diagnostic categories such as MCI or in association with therapeutic agents of different nature such as cholinesterase or antioxidant drugs. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Dementia is a clinical condition characterized by global, and usually progressive impairment of cognitive functions. These functions include memory, judgement, reasoning, perception and personality, and impairments lead to difficulties in daily life and to inappropriate behaviour. It is commonest in later life and is most often caused by Alzheimer's disease and inadequate blood supply to the brain, but is also a feature of some other diseases.</P>
<P>Nicergoline, 8-beta-(5-bromonicotinoylhydroxymethyl)-1,6-dimethyl-10alpha-metoxyergoline, is an ergot derivative which has been registered in over fifty countries and has been used for more than three decades for the treatment of cognitive, affective, and behavioural disorders of older people. During the time it has been in use, the rationale for its clinical use has evolved. Initially regarded as a vasoactive drug, it was mainly prescribed for cerebrovascular disorders. Since then, findings suggesting a more complex pharmacological profile of nicergoline have led to its being considered for the treatment of other forms of dementia, including Alzheimer's Disease. Although cholinergic deficits are the major current targets for pharmacological intervention in Alzheimer's dementia, a wide variety of other neurotransmitter changes can be identified in the disease. Nicergoline has been demonstrated to increase the availability of acetylcholine both through an increased release from cholinergic terminals and a selective inhibition of acetyl cholinesterase. Nicergoline may also enhance noradrenaline and dopamine turnover in some areas of the brain. Nicergoline has a positive effect on the signal transduction system stimulating the phosphoinositide pathway which is specifically impaired in Alzheimer's dementia. Other useful actions of nicergoline in dementia are an increase of phosphoinositide-PKC translocation which helps in combating beta-amyloid deposition and in retarding the reduction in nerve-growth factor (NGF) which may help in preventing the loss of cholinergic neurons. </P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine whether there is evidence of efficacy of nicergoline in the treatment of dementia and other age-associated forms of cognitive decline,and to assess the safety and tolerability of the drug. </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All unconfounded, double-blind, randomized, placebo-controlled, published and unpublished trials were reviewed. Non-randomized trials were excluded. Open trials were considered for inclusion if patients were randomized to the different treatment groups. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>All patients diagnosed as having dementia or other cognitive disorder defined according to classification criteria accepted at the time of each study. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Nicergoline given at any dose for more than one day with placebo control. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>1. Cognitive function (as measured by psychometric tests). <BR/>2. Clinical impression (such as CIBIC or other clinical global measures of change). <BR/>3. Functional performance including dependency. <BR/>4. Behavioural disturbance. <BR/>5. Safety and acceptability as measured by the incidence of adverse effects (including side-effects) leading to withdrawal. <BR/>6. Death <BR/>7. Effect on carer <BR/>8. Use of services <BR/>9. Quality of life. </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>1. The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 4 May 2001 using the term nicergolin* and sermion. The Specialized Register at that time contained records from the following databases:</P>
<P>CCTR/Central: January 2001 (issue 1);<BR/>MEDLINE: 1966 to December 2000;<BR/>EMBASE: 1980 to December 2000;<BR/>PsycLit: 1887 to December 2000;<BR/>CINAHL:1982 to December 2000;<BR/>SIGLE (Grey Literature in Europe): 1980 to December 2000;<BR/>ISTP (Index to Scientific and Technical Proceedings): to May 2000;<BR/>INSIDE (BL database of Conference Proceedings and Journals): to June 2000;<BR/>Aslib Index to Theses (UK and Ireland theses): 1970 to March 2001;<BR/>Dissertation Abstract (USA): 1861 to March 2001;<BR/>ADEAR (Alzheimer's Disease Clinical Trials Database): to March 2001;<BR/>National Research Register (including the MRC Clinical Trials Directory): January 2001 (issue 1) <BR/>Alzheimers Society Trials Database: to March 2001;<BR/>Glaxo-Wellcome Trials Database: to March 2001;<BR/>Centerwatch Trials Database: to December 2000.</P>
<P>The search strategies used to identify relevant records in MEDLINE, EMBASE, PsycInfo and CINAHL can be found in the Group's module.</P>
<P>2. Reference search. The reference lists of all obtained studies were checked. <BR/>3. Pharmaceutical company Pharmacia &amp; Upjohn, owners of the rights to produce and market nicergoline in various different countries, was asked to provide data and reports of clinical trials. In case of unavailability of numerical data in published studies, the authors of each paper, were asked for any published or unpublished data. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>A single reviewer (MF) reviewed the list of articles and discarded irrelevant citations based on the title of the publication and its abstract. In the presence of any suggestion that the article could possibly be relevant, it was retrieved for further assessment. The two reviewers independently selected the trials for inclusion in the review from the culled citation list. Disagreements were resolved by discussion. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Eleven studies (one of which, <LINK REF="STD-Saletu-1995" TYPE="STUDY">Saletu 1995</LINK>, comprised a placebo group and two separate groups of patients, with different clinical diagnoses, and thus was included twice in this review) were found compliant with the inclusion criteria and had numerical data available to be extracted for meta-analysis. Seventy-six other studies were not included predominantly because they did not include a placebo control group (and thus the studies were confounded) or had no control group at all. Other studies were outside the inclusion criteria since they included patients with diagnoses other than dementia or cognitive decline of older people.<BR/>All included studies were classified as category A in regard to allocation concealment and were performed in double-blind, parallel group fashion. Four studies were carried out in single centres, all the others were performed as multicentre.<BR/>This review is based on studies of which the clinical definitions of patients vary both according to the prevalent diagnostic mode of the time and to the different entities considered for inclusion in the individual studies. The various definitions of patients range from "Senile Cognitive Deterioration" to "Cerebral Metabolic and Nutritional Disturbances", from "Hypertension and Leukoaraiosis" to "Senile Cerebral Insufficiency", from "Chronic Cerebrovascular Disorders" to "Multi Infact Dementia (MID)", and from "Senile Dementia" to "Senile Dementia of Alzheimer's Type (SDAT)".<BR/>Most of the studies were performed using a total of 60 mg. of nicergoline per day (in some instances 20 mg three times a day, and in others 30 mg twice a day) and all used oral administration. The length of treatment ranged from a minimum of 4 weeks to a maximum of 2 years.<BR/>The studies were performed in a number of different countries including Italy, USA, Germany, and Austria.<BR/>Not all the data included in this metanalysis are from published sources; four of the included studies were obtained from the internal archives of Pharmacia &amp; Upjohn. </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The two reviewers have assessed the methodological quality of each trial with particular emphasis on allocation concealment. Empirical research has shown that lack of adequate allocation concealment is associated with bias (<LINK REF="REF-Chalmers-1983" TYPE="REFERENCE">Chalmers 1983</LINK>, <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Indeed, concealment has been found to be more important in preventing bias than other components of allocation, such as the generation of the allocation sequence. </P>
<P>The trials were ranked using the Cochrane approach: </P>
<P>Category A (adequate) where the report describes allocation of treatment by: (i) some form of centralized randomized scheme, such as having to provide details of an enrolled participant to an office by phone to receive the treatment group allocation; (ii) some form of randomization scheme controlled by a pharmacy; (iii) numbered or coded containers, such as in a pharmaceutical trial in which capsules from identical-looking numbered bottles are allocated sequentially to enrolled participants; (iv) an on-site or coded computer system, given that the allocations were in a locked, unreadable file that could be accessed only after inputting the characteristics of an enrolled participant; or (v) if assignment envelopes were used, the report should at least specify that they were sequentially numbered, sealed, opaque envelopes; (vi) other combinations of described elements of the process that provide assurance of adequate concealment. </P>
<P>Category B (intermediate) where the report describes allocation of treatment by: (i) use of a 'list' of 'table' to allocate assignments; (ii) use of 'envelopes' or 'sealed envelopes'; (iii) stating the study as 'randomized' without further detail. </P>
<P>Category C (inadequate) where the report describes allocation of treatment by: (i) alternation; (ii) reference to case record numbers, dates of birth, day of week, or any other such approach; (iii) any allocation procedure that is entirely transparent before assignment, such as an open list of random numbers or assignments. Trials which have taken inadequate measures to conceal allocation have been shown to yield more pronounced estimates of treatment effect than trials which have taken adequate measures. Trials with unclear allocation concealment produce estimates less pronounced than inadequately concealed trials, but more pronounced than adequately concealed trials (<LINK REF="REF-Chalmers-1983" TYPE="REFERENCE">Chalmers 1983</LINK>, ).</P>
<P>INCLUSION CRITERIA<BR/>Trials were included if they conformed to categories A or B, while those falling into category C were excluded. </P>
<P>DATA EXTRACTION<BR/>Data were independently extracted by two reviewers and cross-checked. Any discrepancies were discussed. Data were not sought on every patient for each outcome measure, since single patient data were unavailable for most of the studies. To allow an intention-to-treat analysis, data were sought irrespective of compliance, whether or not the patients were subsequently deemed ineligible, or otherwise excluded from treatment or follow-up. Unfortunately, only completers' analyses could be performed. Data for an 'on-treatment' or 'completers' analysis were abstracted from publications or internal reports and used for the analysis. In a study where a cross-over design was used, only data from the first treatment period were included. No titration periods prior to the randomized phase of the study were described in the included studies.</P>
<P>DATA ANALYSIS<BR/>For continuous or ordinal variables (such as psychometric test scores, clinical global impression scales, functional and quality of life scales) the main outcomes of interest are the change in score from baseline to the final assessment. If ordinal scale data appeared to be approximately normally distributed, or if the investigators' analysis suggested parametric tests to be appropriate, the outcome measures were treated as continuous data. For binary outcomes such as global impression the endpoint itself is of interest and the Peto method of the 'typical odds ratio' was used. A test for heterogeneity of the treatment effect between the trials was made using a standard chi-square statistic. If a test of heterogeneity was negative a weighted estimate of the typical treatment effect across trials, the 'typical odds ratio' (i.e. the odds of an unfavourable outcome amongst treatment-allocated patients to the corresponding odds among controls) was calculated using Peto's log-rank test adapted for ordinal data (<LINK REF="REF-Mulrow-1997" TYPE="REFERENCE">Mulrow 1997</LINK>). It was planned that if there was evidence of heterogeneity of the treatment effect within a group of trials then only data from a sub-group of studies showing homogeneity would be pooled. This procedure was not required. The null hypothesis to be tested was that, for any of the above outcomes, nicergoline had no effect compared with placebo. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Results are described for the different outcomes comprising different methods of cognitive assessment, behavioural rating scales, global clinical impression and tolerability to the drug which were identified as the relevant measurements used in the included studies and which have varied according to the time, geographical area, type of patients, and goal of each study.<BR/>
<BR/>Behavioral Rating Scales</P>
<P>Several types of behavioural rating scales were used in the clinical studies with nicergoline. The Sandoz Clinical Assessment Geriatric Scale (SCAG) was the one used with the largest number of patients (in total 814 patients, 405 treated with Nicergoline and 409 with placebo from 7 studies). The results from these diverse studies were homogeneous, even though they included patients with different clinical diagnoses and observed over time periods ranging from 2 months to 12 months. Using the WMD (weighted mean difference) and FE (Fixed Effect) model, the summary effect size was -5.80 [95% CI -8.18, -3.41], p=0.00001 indicating an effect in favour of the active treatment in reducing the behavioural symptoms described by SCAG. This scale has a maximum score of 133 points. The therapeutic effects of nicergoline seem to be evident by 2 months of treatment and maintained for 6 months. In general other behavioural outcome measures which include the GRS, the IADL, and the MACC and were episodically used in few studies, failed to demonstrate statistically significant results although there was a trend favouring treatment.</P>
<P>Cognitive Assessment</P>
<P>Cognitive assessment had been performed for the largest number of subjects with the MMSE and the ADAS-Cog, while only few studies used other measures. The total number of patients who underwent an examination with MMSE was 261, with 132 patients in the nicergoline group and 129 in the placebo group from 3 studies. Even though these individual studies were performed over a long period of time with different acceptable diagnostic criteria, and had a different length of observation ranging from 3 months to 12 months, no significant heterogeneity was found. The effect size of the difference between the treatment groups, favouring nicergoline treatment, was 2.32 [95% CI 1.32, 3.32] using the weighted mean difference and fixed effect model . <BR/>The ADAS-Cog was used in two studies performed for 6 and 12 months, both restricted to Alzheimer's disease patients (in total 342 patients, 176 in the nicergoline group and 166 in the placebo group). In both studies the differences tended to favour the nicergoline group (the total effect size (weighted mean difference) was -1.25 [95% CI -3.62, 1.11]) but this difference was not statistically significant. <BR/>The other results from various cognitive measures tended to favour nicergoline but were based on a small number of cases.(in total 83 patients) One of these studies, performed on a total of 61 patients, provided evidence of a significant effect of nicergoline on a measure of immediate memory when compared with placebo (effect size 3.60 [95% CI 0.50-6.70], p=0.02).<BR/>
<BR/>Clinical Global Impression</P>
<P>Clinical impression was evaluated in a total of 6 different studies with 857 patients, 420 in the nicergoline group and 437 in the placebo group. These results were obtained from periods of observation ranging from 2 months to 12 months and were homogeneous across the studies with chi-square = 7.64 (df = 6, p = 0.27). Using a fixed effects model, the Peto odds ratio for improvement in the subjects treated with nicergoline as opposed to the subjects treated with placebo was 3.33 [95% CI 2.50, 4.43] (p=0.00001).</P>
<P>Tolerability </P>
<P>Tolerability was assessed in 1362 patients, 678 treated with nicergoline and 684 treated with placebo. Safety data were also homogeneous across studies, chi-square = 14.92 (df = 9). Using a fixed effects model, the Peto Odds Ratio for frequency of adverse effects of this drug compared with placebo was 1.51 [95% CI 1.10, 2.07] indicating a modest increase of adverse effects with nicergoline .</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>This review examined controlled studies of nicergoline starting in 1972 and performed with diverse criteria and modalities of evaluation. Despite these potential sources of variability the data used for this meta-analysis were homogeneous in nature. The 11 included studies, out of the 124 studies considered for this review, were all double-blind, placebo controlled clinical studies with extractable numerical data and fulfilled randomization criteria adopted by the Cochrane group. Ten studies are still awaiting an assessment for inclusion, on the assumption that the authors will provide necessary data. At present, the evidence for efficacy of nicergoline is based on studies which have evaluated subjects observed over periods ranging from a minimum of two weeks to a maximum of two years and has been confirmed in different domains such as behaviour, cognition, and clinical judgement. In general, results of this meta-analysis provide some evidence that there are positive effects of nicergoline on cognition and behaviour, and these effects are confirmed by the relevant effect on clinical global impression. There was some evidence of modest problems in the tolerance for this medication. </P>
<P>The evidence of these results is mostly based on studies performed on older patients with mild to moderate cognitive and behavioural impairment of various clinical origins, including chronic cerebrovascular disorders and Alzheimer's dementia. The few studies specifically performed on patients with Alzheimer's disease, even though consistently indicating a trend in favour of the active treatment, were performed with too few people to give a definite answer to the questions concerning the use of nicergoline for this form of dementia.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is some evidence that nicergoline may have benefits for people with dementia and chronic cognitive disorders. Nicergoline is relatively safe and easy to prescribe and use. The bulk of evidence is obtained from disorders with a cerebrovascular origin, but it is not clear whether the effect is restricted to these conditions. There is little available evidence for a useful role in the treatment of Alzheimer's dementia.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Since many of the studies done on nicergoline were carried out long ago, the drug has not been evaluated using currently available diagnostic categories or with or against other therapeutic agent such as cholinesterase inibitors or antioxidants. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank the full and useful cooperation of the Pharmacia&amp;Upjohn personnel in Milan (Italy) who made available the unpublished data in their archives. We also gratefully acknowledge the contribution of Sara Carfagna, the consumer editor.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>In past years one of the authors (MF) has worked as consultant for Farmitalia (later incorporated into Pharmacia) in the development of some clinical studies with nicergoline. None of those studies was of interest for this review owing to the type of patients considered or the research protocol used.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>-MF produced a culled reference list for approval of LF. MF obtained the unpublished references and extracted the data from all references. MF wrote the first draft of the review. <BR/>-LF: checked the analyses and revised the protocol and review.<BR/>-MF: all correspondence</P>
<P>-CDCIG contact editor: Peter Whitehouse</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Amaducci-1999" NAME="Amaducci 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Unpublished internal report from Pharmacia &amp;amp; Upjohn&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Amaducci L, Maurer K, Winblad B, Dom R, Bullock R</AU>
<TI>Efficacy and safety of nicergoline, 30mg tablets b.i.d. for twelve months, in the treatment of probable Alzheimer's disease. A multicentre, multinational, double-blind, randomized, placebo-controlled, parallel group clinical trial</TI>
<SO>Unpublished report</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Baldelli-1993" NAME="Baldelli 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Unpublished internal report from Pharmacia &amp;amp; Upjohn&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Baldelli MV, Pirani A, Toschi A, Ballotti A</AU>
<TI>Association of nicergoline and psychosensory training treatment in a group of elderly patients with cognitive impairment</TI>
<SO>Congress abstract and unpublished report</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Battaglia-1989" NAME="Battaglia 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Battaglia A, Bruni G, Ardia A, Sacchetti G, &amp; the Italian Nicergoline Study Group</AU>
<TI>Nicergoline in Mild to Moderate Dementia: a multicenter, double-blind, placebo-controlled study</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1989</YR>
<VL>37</VL>
<NO>4</NO>
<PG>295-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bes-1999" NAME="Bes 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bes A, Orgogozo JM, Poncet M, Rancurel G, Weber M, Bertholom N, Calvez R, Stehle B.</AU>
<TI>A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis</TI>
<SO>European Journal of Neurology</SO>
<YR>1999</YR>
<VL>6</VL>
<PG>313-322</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Crook-1996" NAME="Crook 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Unpublished internal report from Pharmacia &amp;amp; Upjohn&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Crook TH, Lakin DM</AU>
<TI>A double-blind, randomized, placebo-controlled trial of 30mg b.i.d. nicergoline administered for six months to patients with probable Alzheimer's Disease</TI>
<SO>Unpublished report from Pharmacia &amp; Upjohn</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donoso-1979" NAME="Donoso 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donoso A, Santander M, Sarce H</AU>
<TI>Effect of nicergoline on intellectual performance</TI>
<TO>Efecto de la nicergolina en el deterioro psicorganico senil</TO>
<SO>Revista Medica de Chile</SO>
<YR>1979</YR>
<VL>107</VL>
<PG>817-819</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GCISN-1985" NAME="GCISN 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gruppo Coperativo Italiano per lo Studio della Nicergolina</AU>
<TI>The activity of nicergoline in senile cerebral deterioration: controlled clinical studies vs placebo</TI>
<SO>Giornale di Gerontologia</SO>
<YR>1985</YR>
<VL>Suppl. 62</VL>
<PG>27-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrmann-1997" NAME="Herrmann 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Herrmann WM, Stephan K, Gaede K, Apeceche M</AU>
<TI>A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia</TI>
<SO>Dementia and Geriatric Cognitive Disorders</SO>
<YR>1997</YR>
<VL>8</VL>
<PG>9-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nappi-1997" NAME="Nappi 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nappi G, Bono G, Merlo P, Borromei A, Caltagirone C, Lomeo C, Martucci N, Fabbrini G, Annoni K, Battaglia A</AU>
<TI>Long-term nicergoline treatment of mild to moderate senile dementia</TI>
<SO>Clinical Drug Investigation</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>308-316</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Roelandts-1994" NAME="Roelandts 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Unpublished internal report from Pharmacia-Upjohn&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Roelandts F, Moglia A, Binder H, Jordy C</AU>
<TI>Multicenter, multinational, double-blind, placebo-controlled study of the efficacy and tolerability of nicergoline in patients suffering from mild to moderate senile dementia</TI>
<SO>Unpublished internal report</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saletu-1995" NAME="Saletu 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saletu B, Paulus E, Linzmeyer L, Anderer P, Semlitsch HV, Grunberger J, Wicke L, Neuhold A, Podreka I</AU>
<TI>Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study</TI>
<SO>Psychopharmacology</SO>
<YR>1995</YR>
<VL>117</VL>
<NO>4</NO>
<PG>385-395</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Ardia-1985" NAME="Ardia 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Unpublished internal report from Farmitalia&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Ardia A, Dubini A, Jori MC, Groppi W</AU>
<TI>Multicentric, double-blind, crossover study of nicergoline vs placebo in mild to moderate senile dementia</TI>
<SO>Unpublished internal report</SO>
<YR>1985</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Battaglia-1990" NAME="Battaglia 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Battaglia A, Bruni G, Sacchetti G, Pamparana F</AU>
<TI>A double-blind randomized study of two ergot derivatives in mild to moderate dementia</TI>
<SO>Current Therapeutic Research</SO>
<YR>1990</YR>
<VL>48</VL>
<PG>597-612</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Battaglia-1995b" NAME="Battaglia 1995b" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Battaglia A, Annoni K, Pamparana F, De Paolis C, Bonura M, Stekke W, and Nicergolina Dementia Long Term Study Italian Group</AU>
<TI>Nicergoline in the long term tratment of mild or moderate senile dementia: a multicenter double-blind, randomized, placebo-controlled trial</TI>
<SO>8th European College of Neuropsychopharmacology</SO>
<YR>1995</YR>
<CY>Venice</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bente-1979" NAME="Bente 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bente D, Glatthaar G, Ulrich G, Lewinsky M</AU>
<TI>Quantitative EEG examinations on the vigilance stabilizing effect of nicergoline / Results of a double blind study with gerontopsychiatric patients</TI>
<SO>Arzneimittel Forschung</SO>
<YR>1979</YR>
<VL>29</VL>
<PG>1804-1808</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernini-1977" NAME="Bernini 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernini FP, Muras I, Maglione F, Smaltino F</AU>
<TI>Action of nicergoline on the cerebral circulatory insufficiency due to arteriosclerosis. Clinical and angioserographic evaluation</TI>
<SO>Farmaco</SO>
<YR>1977</YR>
<VL>32</VL>
<PG>32-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blaha-1979" NAME="Blaha 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blaha L, Burkard G, Lehrl S, Kapinas K</AU>
<TI>Psychopathometric double blind study with nicergoline versus placebo in geriatric patients with slight transit syndromes</TI>
<SO>Arzneimittel Forschung</SO>
<YR>1979</YR>
<VL>29</VL>
<PG>1295-1301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brambilla-1978" NAME="Brambilla 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brambilla G, Malisardi PA, Forni G</AU>
<TI>Double blind comparison of 3 dosages of nicergoline in senile dementia</TI>
<SO>Atti dell'Accademia Medica Lombarda</SO>
<YR>1978</YR>
<VL>33</VL>
<PG>37-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cascone-1978" NAME="Cascone 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cascone A, Liverta C, Pollini C</AU>
<TI>Controlled study with nicergoline and placebo in cerebral and peripheral vascular insufficiency in the aged</TI>
<SO>Minerva Cardioangiologica</SO>
<YR>1978</YR>
<VL>26</VL>
<PG>95-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crook-1997a" NAME="Crook 1997a" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crook TH</AU>
<TI>Nicergoline: parallel evolution of clinical trial methodology and drug development in dementias</TI>
<SO>Dementia and Geriatric Cognitive Disorders</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>Suppl 1</NO>
<PG>22-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crook-1997b" NAME="Crook 1997b" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crook TH</AU>
<TI>Nicergoline in the treatment of probable Alzheimer's disease: preliminary results of a double-blind, randomized, placebo-controlled study</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1997</YR>
<VL>150</VL>
<NO>Suppl</NO>
<PG>18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dauverchain-1979" NAME="Dauverchain 1979" YEAR="1979">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dauverchain J</AU>
<TI>The role of nicergoline in the symptomatic treatment of arterial hypertension and chronic cerebrovascular insufficiency. A study on 359 observations</TI>
<SO>Arzneimittel Forschung</SO>
<YR>1979</YR>
<VL>29</VL>
<PG>1308-1310</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Efimov-1991" NAME="Efimov 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Efimov AS, Man'kovskii BN</AU>
<TI>The effect of sermion on brain function in diabetics</TI>
<SO>Vrachebnoe Delo</SO>
<YR>1991</YR>
<VL>11</VL>
<PG>73-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fabbrini-1995" NAME="Fabbrini 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fabbrini G, Martucci N, Battaglia A, Pamparana F, Annoni K</AU>
<TI>Nicergoline in the treatment of dementia: the effects on cerebral blood flow measured by SPECT</TI>
<SO>8th European College of Neuropsychopharmacology Congress</SO>
<YR>1995</YR>
<CY>Venice</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gara-1993" NAME="Gara 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gara II</AU>
<TI>The effect of pentoxifylline and nicergoline on the systemic and cerebral hemodynamics and on the blood rheological properties in patients with an ischemic stroke and atherosclerotic lesions of the major cerebral arteries</TI>
<SO>Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova</SO>
<YR>1993</YR>
<VL>93</VL>
<PG>28-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guardamagna-1972" NAME="Guardamagna 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guardamagna C, Negri S</AU>
<TI>Clinical efficacy of nicergoline in cerebrovascular diseases. Statistical study</TI>
<SO>Minerva Cardioangiologica</SO>
<YR>1972</YR>
<VL>20</VL>
<PG>636-641</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iliff-1979" NAME="Iliff 1979" YEAR="1979">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Iliff LD, Du Boulay GH, Marshall J, Ross Russell RW, Symon L</AU>
<TI>Effects of nicergoline on cerebral blood flow</TI>
<SO>Arzneimittel Forschung</SO>
<YR>1979</YR>
<VL>29</VL>
<PG>1277-1278</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaemmerer-1980" NAME="Kaemmerer 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaemmerer E</AU>
<TI>Effectiveness of nicergoline in the treatment of chronic cerebrovascular insufficiency</TI>
<SO>Nervenarzt</SO>
<YR>1980</YR>
<VL>51</VL>
<PG>368-372</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kobayashi-1992" NAME="Kobayashi 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kobayashi H, Handa Y, Kawano H, Kubota T</AU>
<TI>Effects of nicergoline (Sermion) in patients with cerebrovascular disease</TI>
<SO>Progress in Medicine</SO>
<YR>1992</YR>
<VL>12</VL>
<PG>2439-2446</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kugler-1984" NAME="Kugler 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kugler J, Heidrich H</AU>
<TI>Nicergoline and cerebral performance insufficiency. Observations in 1 year treatment controls</TI>
<SO>Fortschr Med</SO>
<YR>1984</YR>
<VL>102</VL>
<PG>1091-1096</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kugler-1985" NAME="Kugler 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kugler JE, Meurer-Krull BC</AU>
<TI>Electroencephalography and psychometric measurements during the treatment of cerebral insufficiency with nicergoline and dihydroergotamine mesylate</TI>
<SO>Arzneimittel Forschung</SO>
<YR>1985</YR>
<VL>35</VL>
<PG>1865-1870</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kugler-1990" NAME="Kugler 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kugler J, Groll S, Upmeyer HJ, Schmidt A</AU>
<TI>Nicergoline in the treatment of organic brain syndrome in old age</TI>
<SO>Zeitschrift fur Gerontopsychologie und Psychiatrie</SO>
<YR>1990</YR>
<VL>3</VL>
<PG>277-284</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ladurner-1991" NAME="Ladurner 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ladurner G, Erhart P, Erhart C, Scheiber V</AU>
<TI>Therapy of organic brain syndrome with nicergoline given once a day. [Article in German]</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1991</YR>
<VL>103</VL>
<PG>8-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maiolo-1972" NAME="Maiolo 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maiolo AT, Bianchi Porro G, Galli C, Sessa M</AU>
<TI>Effects of nicergoline on hemodynamics and metabolism of the brain in primary arterial hypertension and in arteriosclerosis</TI>
<SO>Clinica Terapeutica</SO>
<YR>1972</YR>
<VL>62</VL>
<PG>239-252</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Man_x0027_kovskii-1989a" NAME="Man'kovskii 1989a" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Man'kovskii NB, Mints AIa, Karaban' IN</AU>
<TI>Initial dyscirculatory encephalopathy in middle-aged and elderly patients</TI>
<SO>Zh Nevropatol Psikhiatr Im S S Korsakova</SO>
<YR>1989</YR>
<VL>89</VL>
<PG>16-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Man_x0027_kovskii-1989b" NAME="Man'kovskii 1989b" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Man'kowskii NB, Mints AIa, Bachinskaia NIu, Kochubei NV</AU>
<TI>Sermion treatment of middle-aged and elderly patients with initial atherosclerotic encephalopathy</TI>
<SO>Vrachebnoe Delo</SO>
<YR>1989</YR>
<VL>4</VL>
<PG>60-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marolda-1978" NAME="Marolda 1978" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marolda M, Fragassi N, Buscaino GA</AU>
<TI>Clinical evaluation of (-)eburnamonine in comparison with nicergoline in patients suffering from chronic brain ischemia.</TI>
<SO>European Neurology</SO>
<YR>1978</YR>
<VL>17 Suppl 1</VL>
<PG>159-166</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michelangeli-1975" NAME="Michelangeli 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michelangeli J, Sevilla M, Lavagna J, Darcourt G</AU>
<TI>Action of nicergoline (Sermion) in chronic vascular disease in old age</TI>
<SO>Annee Medicale de Psychologie (Paris)</SO>
<YR>1975</YR>
<VL>1</VL>
<PG>499-510</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miletto-1976" NAME="Miletto 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miletto D, Julou M</AU>
<TI>Electroencephalographic study during long-term use of nicergoline</TI>
<SO>Ann Med Psychol (Paris)</SO>
<YR>1976</YR>
<VL>134</VL>
<PG>824-831</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Moglia-no-year" NAME="Moglia no year" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Moglia A, Arrigo A, Battaglia A, Sacchetti G</AU>
<TI>Psychopharmacology of senile dementia: placebo controlled clinical studies with nicergoline</TI>
<SO>unobtainable</SO>
<YR>unobtainable</YR>
<VL>unobtainable</VL>
<PG>117</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montanini-1973" NAME="Montanini 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montanini R, Gasco P, Manfredini G</AU>
<TI>Clinical and electroencephalographic studies of the effect of nicergoline in cerebrovascular diseases</TI>
<SO>Acta Neurologica</SO>
<YR>1973</YR>
<VL>28</VL>
<PG>133-149</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCSG-1990" NAME="NCSG 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nicergoline Cooperative Study Group</AU>
<TI>A double-blind randomized study of two ergot derivatives in mild to moderate dementia</TI>
<SO>Current Therapeutic Research</SO>
<YR>1990</YR>
<VL>48</VL>
<PG>597-612</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nico-1981" NAME="Nico 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nico F, Guercini F, Biagi A, Fanfoni S</AU>
<TI>Cerebral ischemic vasculopathy: clinical and thermographic study in patients treated with papaveroline</TI>
<SO>Clinica Terapeutica</SO>
<YR>1981</YR>
<VL>98</VL>
<PG>195-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-no-author-1989" NAME="no author 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>No author</AU>
<TI>Nicergolin in the treatment of geriatric patients with chronic cerebral insufficiency</TI>
<SO>Folha Medica</SO>
<YR>1989</YR>
<VL>98</VL>
<PG>409-414</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohtomo-1986a" NAME="Ohtomo 1986a" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ohtomo E, Hirai S, Kato N, Araki G, Kuzuya F, Utsumi S, Handa H, Daraj K, Fujishima M</AU>
<TI>Clinical evaluation of TA-079 (nicergoline) in the treatment of cerebrovascular disorders</TI>
<SO>Clinical Evaluation</SO>
<YR>1986</YR>
<VL>14</VL>
<PG>575-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohtomo-1986b" NAME="Ohtomo 1986b" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Otomo E, Hirai S, Hasegawa K, Kato N, Araki G, Kuzuya F, Utsumi S, Handa H, Sarai K, Fujishima M</AU>
<TI>Clinical evaluation of TA-079 (Nicergoline) in the treatment of cerebrovascular disorders</TI>
<SO>Folia Pharmacologica Japonica</SO>
<YR>1986</YR>
<VL>87</VL>
<PG>73-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohtomo-1986c" NAME="Ohtomo 1986c" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ohtomo E, Hirai S, Hasegawa H, Kato N, Araki G, Kuzuya F, Utsumi S, Handa H, Sarai K, Fujishima M</AU>
<TI>Clinical evaluation of TA-079 (Nicergoline) in long-term treatment of cerebrovascular disorders</TI>
<SO>Folia Pharmacologica Japonica</SO>
<YR>1986</YR>
<VL>87</VL>
<PG>451-466</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prencipe-1974" NAME="Prencipe 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prencipe M, Cecconi V, Pisarri F</AU>
<TI>Preliminary study on the effect of a nicergoline composition (F.I. 6714) on cerebral blood flow</TI>
<SO>Farmaco</SO>
<YR>1974</YR>
<VL>29</VL>
<PG>278-284</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saletu-1979a" NAME="Saletu 1979a" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saletu B, Grunberger J, Linzmayer L</AU>
<TI>Determination of the encephalotropic, psychotropic and pharmacodynamic properties of nicergoline by means of quantitative pharmaco- electroencephalography and psychometric analysis</TI>
<SO>Arzneimittel Forschung</SO>
<YR>1979</YR>
<VL>29</VL>
<PG>1251-1261</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saletu-1980" NAME="Saletu 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saletu B, Grunberger J</AU>
<TI>Antihypoxidotic and nootropic drugs: proof of their encephalotropic and pharmacodynamic properties by quantitative EEG investigations</TI>
<SO>Progress in Neuropsychopharmacology</SO>
<YR>1980</YR>
<VL>4</VL>
<PG>469-489</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saletu-1987" NAME="Saletu 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saletu B, Hochmayer I, Grunberger J, Bohmer F, Paroubek J, Wicke L, Neuhold A</AU>
<TI>Therapy of multi-infarct dementia with nicergoline: double-blind, clinical, psychometric and EEG imaging studies with 2 dosage schedules</TI>
<SO>Wien Med Wochenschr</SO>
<YR>1987</YR>
<VL>137</VL>
<PG>513-524</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saletu-1996a" NAME="Saletu 1996a" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saletu B, Paulus E, Linzmayer L, Anderer P, Semlitsch HV, Grunberger J, Wicke L, Neuhold A, Podreka I</AU>
<TI>Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study</TI>
<SO>Folha Medica</SO>
<YR>1996</YR>
<VL>113</VL>
<PG>103-114</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saletu-1996b" NAME="Saletu 1996b" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Saletu B</AU>
<TI>On the relations between symptomatology and brain function in dementias</TI>
<SO>Proceedings of the Fourth International Nice/Springfield Symposium on Advances in Alzheimer Therapy</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saletu-1997" NAME="Saletu 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saletu B, Anderer P, Semlitsch HV</AU>
<TI>Relations between symptomatology and brain function in dementias: double- blind, placebo-controlled, clinical and EEG/ERP mapping studies with nicergoline</TI>
<SO>Dementia and Geriatric Cognitive Disorders</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>Suppl 1</NO>
<PG>12-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samso-1979" NAME="Samso 1979" YEAR="1979">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Samso Dies JM, Villa Bado J, Villalobos J, Iriarte JL, Ordeix R</AU>
<TI>Neurophysiological study of 36 patients with cerebral vascular processes treated with nicergoline</TI>
<SO>Arzneimittel Forschung</SO>
<YR>1979</YR>
<VL>29</VL>
<PG>1301-1307</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1994" NAME="Schneider 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schneider F, Popa R, Mihalas G, Stefaniga P, Mihalas IG, Maties R, Mateescu R</AU>
<TI>Superiority of antagonic-stress composition versus nicergoline in gerontopsychiatry</TI>
<SO>Annals of New York Academy of Sciences</SO>
<YR>1994</YR>
<VL>30</VL>
<PG>332-342</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shtok-1985" NAME="Shtok 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shtok VN, Varlamova IV, Fedorova NV, Timurbaator</AU>
<TI>Clinico-rheographic study of the cerebrovascular effect of alpha-adrenergic blockers in vascular diseases of the brain</TI>
<SO>Zh Nevropatol Psikhiatr Im S S Korsakova</SO>
<YR>1985</YR>
<VL>85</VL>
<PG>1333-1338</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toni-1973" NAME="Toni 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toni E</AU>
<TI>Therapeutic activity of nicergoline in cerebrovascular syndromes</TI>
<SO>Minerva Medica</SO>
<YR>1973</YR>
<VL>64</VL>
<PG>4466-4473</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vesel_x0027_skii-1991" NAME="Vesel'skii 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vesel'skii ISh, Sanik AV</AU>
<TI>The correction of microcirculatory disorders in patients with circulatory encephalopathy</TI>
<SO>Vrachebnoe Delo</SO>
<YR>1991</YR>
<VL>7</VL>
<PG>85-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vesel_x0027_skii-1992" NAME="Vesel'skii 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vesel'skii ISh, Gritsai NN</AU>
<TI>The correction of lipid peroxidation metabolism, the hemostatic system and cerebral hemodynamics in patients with the initial manifestations of cerebral circulatory insufficiency</TI>
<SO>Lik Sprava</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>50-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winblad-2000" NAME="Winblad 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winblad B, Carfagna N, Bonura L, Rossini B,M, Wong EHF, Battaglia A</AU>
<TI>Nicergoline in dementia: a review of its pharmacological properties and therapeutical potential</TI>
<SO>CNS Drugs</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>267-287</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Arrigo-1982" NAME="Arrigo 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arrigo A, Moglia A, Borsotti L,</AU>
<TI>A double-blind, placebo-controlled, crossover trial with nicergoline in patients with senile dementia</TI>
<SO>International Journal of Clinical Pharmacological Research</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>suppl 1</NO>
<PG>33-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blaha-1983" NAME="Blaha 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blaha L</AU>
<TI>Monitoring therapy in the treatment of cerebrovascular insufficiency</TI>
<SO>Fortschr Med</SO>
<YR>1983</YR>
<VL>101</VL>
<PG>1187-1190</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gessner-1985" NAME="Gessner 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gessner B, Voelp A, Klasser M</AU>
<TI>Study of the long-term action of a Ginkgo biloba extract on vigilance and mental performance as determined by means of quantitative pharmaco-EEG and psychometric measurements</TI>
<SO>Arzneimittel Forschung</SO>
<YR>1985</YR>
<VL>35</VL>
<PG>1459-1465</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grel-1975" NAME="Grel 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grel P, Normand F</AU>
<TI>Comparative double-blind study versus placebo of nicergoline in cerebral circulatory insufficiency</TI>
<SO>Psychologie Medicale</SO>
<YR>1975</YR>
<VL>7</VL>
<PG>1789-1793</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karyofilis-1980" NAME="Karyofilis 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karyofilis A</AU>
<TI>Therapy of demonstrated cerebral ischemia with nicergoline</TI>
<SO>Ther Ggw</SO>
<YR>1980</YR>
<VL>119</VL>
<PG>1478-1485</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lebedeva-1990" NAME="Lebedeva 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lebedeva NV, Khrapova EV</AU>
<TI>Use of sermion, Cavinton and trental in patients with cerebrovascular disorders</TI>
<SO>Sov Med</SO>
<YR>1990</YR>
<VL>1</VL>
<PG>60-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Moglia-1991" NAME="Moglia 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Congress Abstract and Pharmacia &amp;amp; Upjohn internal report&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Moglia A, Bergonzoli S, Merlo P, Battaglia A, Valzelli S</AU>
<TI>Demented patients of low or moderate grade treated with nicergoline: preliminary data of a double blind placebo controlled study</TI>
<SO>Pan European Society of Neurology, 2nd Congress</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moglia-1993" NAME="Moglia 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Congress Abstract and internal report from Pharmacia &amp;amp; Upjohn&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Moglia A, Murri L, Battistini N, Battaglia A, Novellini R, Annoni K, Pamparana F,</AU>
<TI>Nicergoline in mild to moderate SDAT and MID: clinical and EEG brain mapping study</TI>
<SO>13th International Congress of Electroencephalography &amp; Clinical Neurophysiology</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nobuhara-1993" NAME="Nobuhara 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nobuhara K</AU>
<TI>A quantitative pharmaco-EEG study on psychotropic properties of cerebral metabolic enhancers: comparison between young and elderly healthy volunteers</TI>
<SO>Seishin Shinkeigaku Zasshi</SO>
<YR>1993</YR>
<VL>95</VL>
<PG>392-416</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saletu-1990" NAME="Saletu 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saletu B, Grunberger J, Linzmayer L, Anderer P</AU>
<TI>Brain protection of nicergoline against hypoxia: EEG brain mapping and psychometry</TI>
<SO>Journal of Neural Transmission, Parkinson's Disease, Dementia Section</SO>
<YR>1990</YR>
<VL>2</VL>
<PG>305-325</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiedenhammer-1991" NAME="Wiedenhammer 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiedenhammer W, Groll S, Ladurner G, Erhart P, Erhart C, Scheiber V</AU>
<TI>Therapy of organic brain syndrome with nicergoline given once a day</TI>
<SO>Zeitschrift Fuer Gerontopsychologie und Psychiatrie</SO>
<YR>1991</YR>
<VL>103</VL>
<PG>1-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zappoli-1987" NAME="Zappoli 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zappoli R, Arnetoli G, Paganini M, Versari A, Battaglia A, Grignani A, Sacchetti G</AU>
<TI>Contingent negative variation and reaction time in patients with presenile idiopathic cognitive decline and presenile Alzheimer-type dementia. Preliminary report on long-term nicergoline treatment</TI>
<SO>Neuropsychobiology</SO>
<YR>1987</YR>
<VL>18</VL>
<PG>149-154</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Chalmers-1983" NAME="Chalmers 1983" NOTES="&lt;p&gt;Chalmers TC, Celano P, Sacks HS, Smith H, Junior. Bias in Treatment Assignment in Controlled Clinical Trials. N Eng J Med, 1983; 309:1358-61.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC, Celano P, Sacks HS, Smith H, Junior.</AU>
<TI>Bias in Treatment Assignment in Controlled Clinical Trials.</TI>
<SO>N Eng J Med</SO>
<YR>1983</YR>
<VL>309</VL>
<PG>1358-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mc-Arthur-1997" NAME="Mc Arthur 1997" TYPE="JOURNAL_ARTICLE">
<AU>Mc Arthur RA, Carfagna N, Banfi L, Cavanus S, Cervini MA, Fariello R</AU>
<TI>Effects of nicergoline on age-related decrements in radial maze performance and acetylcholine levels</TI>
<SO>Brain Research Bulletin</SO>
<YR>1997</YR>
<VL>43</VL>
<PG>305-311</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1997" NAME="Mulrow 1997" NOTES="&lt;p&gt;Mulrow CD, Oxman AD (eds). Cochrane Collaboration Handbook [updated 9 December 1996]. Available in The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration; Issue 1. Oxford: Update Software; 1997. Updated quarterly&lt;/p&gt;" TYPE="BOOK">
<AU>Mulrow CD, Oxman AD (eds)</AU>
<TI>Cochrane Collaboration Handbook [updated 9 December 1996]. Available in The Cochrane Library [database on disk and CDROM].</TI>
<SO>The Cochrane Collaboration; Issue 1, updated quarterly</SO>
<YR>1997</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" NOTES="&lt;p&gt;Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273(5):408-12&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG.</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials.</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-05 16:37:13 +0000" MODIFIED_BY="Helen Collins">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-05 16:37:13 +0000" MODIFIED_BY="Helen Collins" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Amaducci-1999">
<CHAR_METHODS>
<P>multinational, multicentre, double blind, randomized, placebo controlled, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SDAT mild to moderate; 24 patients received nicergoline, 24 placebo;<BR/>age &gt; 50 yr.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nicergoline or Placebo 30mg. twice a day (os) for 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>ADAScog, IADL, CGIC for efficacy; adverse events for safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>CGIC data were not available. ITT (LOCF) analysis is available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Baldelli-1993">
<CHAR_METHODS>
<P>single centre, double blind, randomized, placebo controlled, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Senile cognitive deterioration mild to moderate; 20 patients recived nicergoline, 20 placebo; age &gt; 58 yr.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nicergoline or Placebo 20mg. trice a day (os) for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>MMSE, IADL for efficacy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Patients received a concomitant psychosensory training</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Battaglia-1989">
<CHAR_METHODS>
<P>multicentre, double blind, randomized, placebo controlled, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Dementia mild to moderate; 158 patients received nicergoline, 157 placebo; age &gt; 55 yr.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nicergoline or Placebo 20mg. twice a day (os) for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SCAG for efficacy; HR and blood pressure for safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Only completers' analysis is available for 101nicergoline and 100 placebo cases (unpublished report from Pharmacia-Upjohn)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bes-1999">
<CHAR_METHODS>
<P>multicentre, double blind, randomized, placebo controlled, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Hypertension &amp; leukoaraiosis; <BR/>36 patients received nicergoline, 36 placebo; age &gt; 60 yr.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nicergoline or Placebo 30mg. twice a day (os) for 24 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rey Auditory Verbal Learning Test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ITT (LOCF) analysis is available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Crook-1996">
<CHAR_METHODS>
<P>multicentre, double blind, randomized, placebo controlled, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SDAT mild to moderate; 74 patients received nicergoline, 75 placebo; age &gt; 50 yr.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nicergoline or Placebo 30mg. twice a day (os) for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>ADAScog, CGIC for efficacy; adverse events for safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ITT (LOCF) analysis is available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Donoso-1979">
<CHAR_METHODS>
<P>single centre, double blind, randomized, placebo controlled, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Senile cognitive deterioration with no signs of dementia; 11 patients received nicergoline, 11 placebo; age &gt; 65 yr.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nicergoline or Placebo 10mg. trice a day (os) for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WAIS IQ</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Completers' analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-GCISN-1985">
<CHAR_METHODS>
<P>multicentre, double blind, randomized, placebo controlled, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Senile cerebral insufficiency mild to moderate; 82 patients received nicergoline, 80 placebo; age &gt; 55 yr.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nicergoline or Placebo 20mg. twice a day (os) for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SCAG for efficacy; adverse events for safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>It describes also a crossover study but with no data available for inclusion in this review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Herrmann-1997">
<CHAR_METHODS>
<P>multicentre, double blind, randomized, placebo controlled, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>MID; 70 patients received nicergoline, 69 placebo; age 55-85 yr.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nicergoline or Placebo 30mg. twice a day (os) for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SCAG, MMSE, CGI for efficacy; adverse events for safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nappi-1997">
<CHAR_METHODS>
<P>multicentre, double blind, randomized, placebo controlled, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SDAT or MID mild to moderate; 51patients received nicergoline, 50 placebo; age 60-80 yr.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nicergoline or Placebo 30mg. twice a day (os) for 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SCAG, MMSE, CGI for efficacy; adverse events for safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Roelandts-1994">
<CHAR_METHODS>
<P>multinational, multicentre, double blind, randomized, placebo controlled, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Senile dementia mild to moderate; 82 patients received nicergoline, 80 placebo; age &gt; 55.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nicergoline or Placebo 30mg. twice a day (os) for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SCAG, GRS, MACC for efficacy; adverse events for safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Saletu-1995">
<CHAR_METHODS>
<P>single centre, double blind, randomized, placebo controlled, parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>MID mild to moderate; 24 patients received nicergoline, 26 placebo; age &gt; 60 yr.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nicergoline or Placebo 30mg. twice a day (os) for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SCAG, MMSE, CGI, EEG/ERP for efficacy; side effects for safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ardia-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>cross-over study with no data divided for each arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Battaglia-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled study vs another active drug</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Battaglia-1995b">
<CHAR_REASON_FOR_EXCLUSION>
<P>preliminary data of another included study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bente-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled study vs dihydroergotoxin-mesylate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bernini-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blaha-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>clinical study with geriatric patients with transitory cognitive and behavioural deficits</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brambilla-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled study between three different dosage of nicergoline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cascone-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>data not available in numerical form</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Crook-1997a">
<CHAR_REASON_FOR_EXCLUSION>
<P>not clinical study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Crook-1997b">
<CHAR_REASON_FOR_EXCLUSION>
<P>preliminary results of another included study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dauverchain-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled study. Chronic cerebrovascular insufficiency</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Efimov-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled clinical study, Diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fabbrini-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gara-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled study vs pentoxifylline in cerebral atherosclerosis patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guardamagna-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iliff-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled study. Blood flow in patients with cerebrovascular disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kaemmerer-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kobayashi-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kugler-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kugler-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled study vs dihydroergotamine mesilate in patients with cerebral insufficiency</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kugler-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>clinical study on normal subjects taking barbiturates</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ladurner-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled clinical study vs co-dergocrine mesilate in patients with multinfarct dementia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maiolo-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Man_x0027_kovskii-1989a">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled study vs prostacyclin in brain hypoxia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Man_x0027_kovskii-1989b">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marolda-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled study vs eburnamonine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Michelangeli-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>clinical study performed with chronic cerebrovascular patients included without a formal assessment of cognitive deficits but on the basis only of clinical signs of vascular pathology</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miletto-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moglia-no-year">
<CHAR_REASON_FOR_EXCLUSION>
<P>a review of different studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Montanini-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-NCSG-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled study vs ergoloid mesylates</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nico-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled study vs papaveroline on cerebral ischaemic vasculopathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-no-author-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>data presented in another included study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ohtomo-1986a">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled study vs Ca-hopantenate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ohtomo-1986b">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled study vs Hydergine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ohtomo-1986c">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prencipe-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saletu-1979a">
<CHAR_REASON_FOR_EXCLUSION>
<P>multiple treatments controlled study run in a cross-over fashion with each patient taking all different treatments at different periods of the observation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saletu-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>review with no data in numerical format</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saletu-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled study vs a different dosage of nicergoline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saletu-1996a">
<CHAR_REASON_FOR_EXCLUSION>
<P>same data of another included study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saletu-1996b">
<CHAR_REASON_FOR_EXCLUSION>
<P>same data of another included study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saletu-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>same data of another included study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Samso-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled neurophysiological study on patients with chronic cerebrovascular disorders</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schneider-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled study vs antagonic-stress</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shtok-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>controlled study vs dihydroergotoxin on cerebral haemodynamics of patients with acute and chronic cerebrovascular diseases</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Toni-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vesel_x0027_skii-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>not placebo controlled clinical study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vesel_x0027_skii-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>not placebo controlled clinical study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Winblad-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a clinical study, a review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Arrigo-1982">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Blaha-1983">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Gessner-1985">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Grel-1975">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Karyofilis-1980">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Lebedeva-1990">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Moglia-1991">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Moglia-1993">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Nobuhara-1993">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Saletu-1990">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Wiedenhammer-1991">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Zappoli-1987">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-11-05 16:37:13 +0000" MODIFIED_BY="Helen Collins">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-11-05 16:37:13 +0000" MODIFIED_BY="Helen Collins" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Behavioral Rating Scales</NAME>
<CONT_OUTCOME CHI2="6.320379712128763" CI_END="-3.2824583615340437" CI_START="-8.174519362490635" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.728488862012339" ESTIMABLE="YES" I2="20.890828910088484" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.27628084054040625" P_Q="0.5679225418431192" P_Z="4.429406421905383E-6" Q="1.1315410345509997" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="381" TOTAL_2="385" UNITS="" WEIGHT="99.99999999999999" Z="4.590143848650938">
<NAME>SCAG total scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.14182980930795" CI_START="-14.14182980930795" DF="0.0" EFFECT_SIZE="-3.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="1.0" P_Z="0.519177274681768" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="5.283127817780871" Z="0.6446141376824269">
<NAME>Scag total score after 2 months</NAME>
<CONT_DATA CI_END="7.14182980930795" CI_START="-14.14182980930795" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="-11.0" MEAN_2="-7.5" ORDER="1" SD_1="22.63" SD_2="14.55" SE="5.42960477501084" STUDY_ID="STD-Saletu-1995" TOTAL_1="24" TOTAL_2="26" WEIGHT="5.283127817780871"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.188838677577763" CI_END="-2.3304505532579474" CI_START="-8.03316914545988" DF="3.0" EFFECT_SIZE="-5.181809849358913" ESTIMABLE="YES" I2="42.18359470369099" ID="CMP-001.01.02" NO="2" P_CHI2="0.15848057877142185" P_Z="3.6822785683483913E-4" STUDIES="4" TAU2="0.0" TOTAL_1="306" TOTAL_2="309" WEIGHT="73.59017656719473" Z="3.561866332793006">
<NAME>SCAG total score after 6 months</NAME>
<CONT_DATA CI_END="2.8053249050820983" CI_START="-6.345324905082098" EFFECT_SIZE="-1.77" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="0.07" ORDER="1" SD_1="16.67" SD_2="16.3" SE="2.3343923363754016" STUDY_ID="STD-Roelandts-1994" TOTAL_1="96" TOTAL_2="104" WEIGHT="28.581160357465606"/>
<CONT_DATA CI_END="-3.5758138346871062" CI_START="-15.02418616531289" EFFECT_SIZE="-9.299999999999999" ESTIMABLE="YES" MEAN_1="-14.7" MEAN_2="-5.4" ORDER="2" SD_1="18.48" SD_2="22.69" SE="2.9205568114845692" STUDY_ID="STD-Battaglia-1989" TOTAL_1="101" TOTAL_2="100" WEIGHT="18.259809268949535"/>
<CONT_DATA CI_END="-1.6068943736911097" CI_START="-15.413105626308887" EFFECT_SIZE="-8.509999999999998" ESTIMABLE="YES" MEAN_1="-14.2" MEAN_2="-5.69" ORDER="3" SD_1="17.1" SD_2="21.37" SE="3.522057385115086" STUDY_ID="STD-Herrmann-1997" TOTAL_1="61" TOTAL_2="60" WEIGHT="12.5555198454545"/>
<CONT_DATA CI_END="2.6825343302068143" CI_START="-10.302534330206814" EFFECT_SIZE="-3.8100000000000005" ESTIMABLE="YES" MEAN_1="-16.87" MEAN_2="-13.06" ORDER="4" SD_1="19.84" SD_2="11.17" SE="3.3125783848168115" STUDY_ID="STD-GCISN-1985" TOTAL_1="48" TOTAL_2="45" WEIGHT="14.193687095325096"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.8683527876888393" CI_START="-13.51164721231116" DF="0.0" EFFECT_SIZE="-8.19" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" NO="3" P_CHI2="1.0" P_Z="0.002558132720017891" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="50" WEIGHT="21.12669561502439" Z="3.0163790256986442">
<NAME>SCAG total score after 12 months</NAME>
<CONT_DATA CI_END="-2.8683527876888393" CI_START="-13.51164721231116" EFFECT_SIZE="-8.19" ESTIMABLE="YES" MEAN_1="-3.61" MEAN_2="4.58" ORDER="1" SD_1="14.88" SD_2="12.31" SE="2.715176020726725" STUDY_ID="STD-Nappi-1997" TOTAL_1="51" TOTAL_2="50" WEIGHT="21.12669561502439"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0976242238261775" CI_START="-3.497624223826177" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.30600192036120333" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="104" UNITS="" WEIGHT="100.0" Z="1.0236472775045038">
<NAME>GRS total scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0976242238261775" CI_START="-3.497624223826177" DF="0.0" EFFECT_SIZE="-1.2" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="0.30600192036120333" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="104" WEIGHT="100.0" Z="1.0236472775045038">
<NAME>GRS total score after 6 months</NAME>
<CONT_DATA CI_END="1.0976242238261775" CI_START="-3.497624223826177" EFFECT_SIZE="-1.2" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="0.6" ORDER="1" SD_1="8.77" SD_2="7.72" SE="1.1722787979521787" STUDY_ID="STD-Roelandts-1994" TOTAL_1="96" TOTAL_2="104" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.106020854702356" CI_START="-2.3060208547023557" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.4" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.45905540342854023" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="104" UNITS="" WEIGHT="100.0" Z="0.7404031671528336">
<NAME>MACC total scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.106020854702356" CI_START="-2.3060208547023557" DF="0.0" EFFECT_SIZE="1.4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="1.0" P_Z="0.45905540342854023" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="104" WEIGHT="100.0" Z="0.7404031671528336">
<NAME>MACC total scores after 6 months</NAME>
<CONT_DATA CI_END="5.106020854702356" CI_START="-2.3060208547023557" EFFECT_SIZE="1.4" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="-0.2" ORDER="1" SD_1="12.94" SD_2="13.8" SE="1.8908617117125495" STUDY_ID="STD-Roelandts-1994" TOTAL_1="96" TOTAL_2="104" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.09891320625345736" CI_END="0.36473478992020136" CI_START="-1.6951548654440274" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.665210037761913" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.753137771849544" P_Q="0.753137771849544" P_Z="0.20555567038126477" Q="0.09891320625345736" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="121" TOTAL_2="113" UNITS="" WEIGHT="100.0" Z="1.2658811240423884">
<NAME>IADL total score</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.1981507502397175" CI_START="-2.798150750239717" DF="0.0" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="1.0" P_Z="0.8139217386387018" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="16.997718690474326" Z="0.23536978114935383">
<NAME>IADL total score after 3 months</NAME>
<CONT_DATA CI_END="2.1981507502397175" CI_START="-2.798150750239717" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.2" ORDER="1" SD_1="4.1" SD_2="3.96" SE="1.274590130198724" STUDY_ID="STD-Baldelli-1993" TOTAL_1="20" TOTAL_2="20" WEIGHT="16.997718690474326"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.39049578230449866" CI_START="-1.870495782304499" DF="0.0" EFFECT_SIZE="-0.7400000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="1.0" P_Z="0.1995084209486849" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="93" WEIGHT="83.00228130952567" Z="1.2829533477808082">
<NAME>IADL total score after 12 months</NAME>
<CONT_DATA CI_END="0.39049578230449866" CI_START="-1.870495782304499" EFFECT_SIZE="-0.7400000000000001" ESTIMABLE="YES" MEAN_1="0.86" MEAN_2="1.6" ORDER="1" SD_1="4.82" SD_2="3.09" SE="0.5767941611283193" STUDY_ID="STD-Amaducci-1999" TOTAL_1="101" TOTAL_2="93" WEIGHT="83.00228130952567"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Cognitive Assessment</NAME>
<CONT_OUTCOME CHI2="1.2418777570926436" CI_END="3.3241993734289084" CI_START="1.3160821653372239" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.320140769383066" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.53743992636476" P_Q="0.53743992636476" P_Z="5.926044639636957E-6" Q="1.2418777570926436" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="129" UNITS="" WEIGHT="100.0" Z="4.529010885151721">
<NAME>MMSE total score</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.3493760801603027" CI_START="-0.5493760801603025" DF="0.0" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="1.0" P_Z="0.15924836077345378" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="26.529365227633043" Z="1.4076040053443324">
<NAME>MMSE total score after 3 months</NAME>
<CONT_DATA CI_END="3.3493760801603027" CI_START="-0.5493760801603025" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="0.2" ORDER="1" SD_1="3.18" SD_2="3.11" SE="0.9945979087048192" STUDY_ID="STD-Baldelli-1993" TOTAL_1="20" TOTAL_2="20" WEIGHT="26.529365227633043"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.0190640047438215" CI_START="1.0209359952561774" DF="0.0" EFFECT_SIZE="2.5199999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" NO="2" P_CHI2="1.0" P_Z="9.849335070488614E-4" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="59" WEIGHT="44.861911262791594" Z="3.2947954359593803">
<NAME>MMSE total score after 6 months</NAME>
<CONT_DATA CI_END="4.0190640047438215" CI_START="1.0209359952561774" EFFECT_SIZE="2.5199999999999996" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="1.28" ORDER="1" SD_1="3.69" SD_2="4.62" SE="0.7648426280116613" STUDY_ID="STD-Herrmann-1997" TOTAL_1="61" TOTAL_2="59" WEIGHT="44.861911262791594"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.737196871870739" CI_START="0.9828031281292609" DF="0.0" EFFECT_SIZE="2.86" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.03" NO="3" P_CHI2="1.0" P_Z="0.0028256051413114093" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="50" WEIGHT="28.60872350957537" Z="2.9860996892661245">
<NAME>MMSE total score after 12 months</NAME>
<CONT_DATA CI_END="4.737196871870739" CI_START="0.9828031281292609" EFFECT_SIZE="2.86" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="-2.84" ORDER="2" SD_1="5.02" SD_2="4.6" SE="0.9577711053253164" STUDY_ID="STD-Nappi-1997" TOTAL_1="51" TOTAL_2="50" WEIGHT="28.60872350957537"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.17353109260707905" CI_END="1.1098767650810009" CI_START="-3.617959485081041" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2540413600000202" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.6769927901680997" P_Q="0.6769927901680997" P_Z="0.29845764592234847" Q="0.17353109260707905" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="176" TOTAL_2="166" UNITS="" WEIGHT="100.0" Z="1.039746628551032">
<NAME>ADAS-cog</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.280419840978131" CI_START="-4.480419840978131" DF="0.0" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" NO="1" P_CHI2="1.0" P_Z="0.7618483883748546" STUDIES="1" TAU2="0.0" TOTAL_1="74" TOTAL_2="72" WEIGHT="37.11140769230573" Z="0.3030544216647459">
<NAME>ADAS-cog after 6 months</NAME>
<CONT_DATA CI_END="3.280419840978131" CI_START="-4.480419840978131" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.5" ORDER="1" SD_1="11.95" SD_2="11.97" SE="1.9798424213844679" STUDY_ID="STD-Crook-1996" TOTAL_1="74" TOTAL_2="72" WEIGHT="37.11140769230573"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3408937314247593" CI_START="-4.620893731424759" DF="0.0" EFFECT_SIZE="-1.6399999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" NO="2" P_CHI2="1.0" P_Z="0.28089344458993326" STUDIES="1" TAU2="0.0" TOTAL_1="102" TOTAL_2="94" WEIGHT="62.88859230769426" Z="1.0783145003660866">
<NAME>ADAS-cog after 12 months</NAME>
<CONT_DATA CI_END="1.3408937314247593" CI_START="-4.620893731424759" EFFECT_SIZE="-1.6399999999999997" ESTIMABLE="YES" MEAN_1="2.18" MEAN_2="3.82" ORDER="1" SD_1="10.71" SD_2="10.57" SE="1.5208920954352572" STUDY_ID="STD-Amaducci-1999" TOTAL_1="102" TOTAL_2="94" WEIGHT="62.88859230769426"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.700534253608609" CI_START="0.49946574639139163" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.02286426994101166" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="31" UNITS="" WEIGHT="100.0" Z="2.275695014861424">
<NAME>AVLT, immediate memory</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.700534253608609" CI_START="0.49946574639139163" EFFECT_SIZE="3.6" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="-2.6" ORDER="1" SD_1="7.2" SD_2="4.9" SE="1.5819342998469497" STUDY_ID="STD-Bes-1999" TOTAL_1="30" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.27006146999188" CI_START="-6.27006146999188" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.787472719476577" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="11" UNITS="" WEIGHT="100.0" Z="0.269593866933596">
<NAME>WAIS IQ</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.27006146999188" CI_START="-6.27006146999188" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="2.73" MEAN_2="1.73" ORDER="1" SD_1="9.79" SD_2="7.45" SE="3.7092831946592884" STUDY_ID="STD-Donoso-1979" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Clinical Evaluation</NAME>
<DICH_OUTCOME CHI2="7.6178379971747505" CI_END="4.5955464253394105" CI_START="2.479739133305473" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.375760108455015" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="92" I2="34.36457953221945" I2_Q="59.542633533260116" ID="CMP-003.01" LOG_CI_END="0.6623371578115065" LOG_CI_START="0.3944059957758517" LOG_EFFECT_SIZE="0.5283715767936792" METHOD="PETO" NO="1" P_CHI2="0.17859316665852298" P_Q="0.08443805908180824" P_Z="1.0732407653710017E-14" Q="4.94347550190694" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="396" TOTAL_2="413" WEIGHT="100.0" Z="7.730263647589006">
<NAME>Clinical Global Impression (number showing improvement)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.833640407687497" CI_START="1.8676888225783979" DF="0.0" EFFECT_SIZE="5.607138488814237" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="1.2261780457444154" LOG_CI_START="0.27130451970210906" LOG_EFFECT_SIZE="0.7487412827232622" NO="1" P_CHI2="1.0" P_Z="0.002114092018729227" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="7.873262837989905" Z="3.073717948717949">
<NAME>CGI after 2 months</NAME>
<DICH_DATA CI_END="16.833640407687497" CI_START="1.8676888225783979" EFFECT_SIZE="5.607138488814237" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="1.2261780457444154" LOG_CI_START="0.27130451970210906" LOG_EFFECT_SIZE="0.7487412827232622" ORDER="1" O_E="5.48" SE="0.5608974358974359" STUDY_ID="STD-Saletu-1995" TOTAL_1="24" TOTAL_2="26" VAR="3.1785795918367348" WEIGHT="7.873262837989905"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.67436249526781" CI_END="3.9895303557333266" CI_START="1.9880659723342118" DF="3.0" EFFECT_SIZE="2.8162829307134305" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="80" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.6009217739027293" LOG_CI_START="0.2984307920056176" LOG_EFFECT_SIZE="0.4496762829541734" NO="2" P_CHI2="0.44460177679261914" P_Z="5.633917212511424E-9" STUDIES="4" TAU2="0.0" TOTAL_1="321" TOTAL_2="337" WEIGHT="78.45517437641834" Z="5.827276659717427">
<NAME>CGI after 6 months</NAME>
<DICH_DATA CI_END="5.2639387064670435" CI_START="1.371280721361412" EFFECT_SIZE="2.686696422487361" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" LOG_CI_END="0.721310823691363" LOG_CI_START="0.13712637036820582" LOG_EFFECT_SIZE="0.4292185970297844" ORDER="1" O_E="8.393034825870647" SE="0.3431528396417042" STUDY_ID="STD-Battaglia-1989" TOTAL_1="101" TOTAL_2="100" VAR="8.49228979480706" WEIGHT="21.03519126046464"/>
<DICH_DATA CI_END="5.214793856639341" CI_START="0.8475046697464594" EFFECT_SIZE="2.1022754684548337" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.7172371452278395" LOG_CI_START="-0.07185790015788088" LOG_EFFECT_SIZE="0.32268962253497935" ORDER="2" O_E="3.458333333333334" SE="0.4635183357430433" STUDY_ID="STD-Crook-1996" TOTAL_1="55" TOTAL_2="65" VAR="4.654426353874883" WEIGHT="11.528898674816078"/>
<DICH_DATA CI_END="9.424048887211208" CI_START="2.2756862139080587" EFFECT_SIZE="4.6310018496889125" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="34" LOG_CI_END="0.9742375303495411" LOG_CI_START="0.35711237856527106" LOG_EFFECT_SIZE="0.6656749544574061" ORDER="3" O_E="11.664233576642339" SE="0.36250236897684907" STUDY_ID="STD-Herrmann-1997" TOTAL_1="69" TOTAL_2="68" VAR="7.60988864617188" WEIGHT="18.849505493906737"/>
<DICH_DATA CI_END="4.234330666683388" CI_START="1.2928483279394702" EFFECT_SIZE="2.3397323185280063" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="24" LOG_CI_END="0.6267847698639653" LOG_CI_START="0.11154757808795397" LOG_EFFECT_SIZE="0.36916617397595963" ORDER="4" O_E="9.280000000000001" SE="0.3026528769144617" STUDY_ID="STD-Roelandts-1994" TOTAL_1="96" TOTAL_2="104" VAR="10.917177889447235" WEIGHT="27.041578947230878"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.420074127402593" CI_START="3.0956276880417923" DF="0.0" EFFECT_SIZE="7.129546697265271" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="5" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="1.2153751133832538" LOG_CI_START="0.4907487224397833" LOG_EFFECT_SIZE="0.8530619179115184" NO="3" P_CHI2="1.0" P_Z="3.936429576631901E-6" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="50" WEIGHT="13.671562785591759" Z="4.614710853995584">
<NAME>CGI after 12 months</NAME>
<DICH_DATA CI_END="16.420074127402593" CI_START="3.0956276880417923" EFFECT_SIZE="7.129546697265271" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="5" LOG_CI_END="1.2153751133832538" LOG_CI_START="0.4907487224397833" LOG_EFFECT_SIZE="0.8530619179115184" ORDER="1" O_E="10.841584158415841" SE="0.42564912899867946" STUDY_ID="STD-Nappi-1997" TOTAL_1="51" TOTAL_2="50" VAR="5.519458876580727" WEIGHT="13.671562785591759"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Tolerability</NAME>
<DICH_OUTCOME CHI2="14.739152913372406" CI_END="2.0583410917581157" CI_START="1.0758578869096564" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.4881137380987388" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="120" I2="45.72279664225593" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.31351734418437505" LOG_CI_START="0.03175490794089413" LOG_EFFECT_SIZE="0.17263612606263462" METHOD="PETO" NO="1" P_CHI2="0.06442045604822966" P_Q="1.0" P_Z="0.01631713277016111" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="654" TOTAL_2="660" WEIGHT="99.99999999999999" Z="2.401743781210715">
<NAME>total number suffering at least one adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.093657828022883" CI_START="1.230663379849625" EFFECT_SIZE="2.9546412503265755" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="51" LOG_CI_END="0.8508702358718265" LOG_CI_START="0.09013927773572032" LOG_EFFECT_SIZE="0.4705047568037734" ORDER="1" O_E="5.425531914893618" SE="0.44685713048812364" STUDY_ID="STD-Amaducci-1999" TOTAL_1="73" TOTAL_2="68" VAR="5.007980340166849" WEIGHT="13.718417214765648"/>
<DICH_DATA CI_END="7.496360101724377" CI_START="0.9437012389296239" EFFECT_SIZE="2.65976019886378" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8748504405312043" LOG_CI_START="-0.025165474791508765" LOG_EFFECT_SIZE="0.4248424828698477" ORDER="2" O_E="3.5" SE="0.5286738038111942" STUDY_ID="STD-Battaglia-1989" TOTAL_1="153" TOTAL_2="153" VAR="3.5778688524590163" WEIGHT="9.800896633734052"/>
<DICH_DATA CI_END="4.598204055619692" CI_START="0.565578919629325" EFFECT_SIZE="1.6126522508007006" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.6625882401527565" LOG_CI_START="-0.24750678602033951" LOG_EFFECT_SIZE="0.20754072706620844" ORDER="3" O_E="1.6721311475409841" SE="0.5345943234171125" STUDY_ID="STD-Bes-1999" TOTAL_1="30" TOTAL_2="31" VAR="3.4990593926363878" WEIGHT="9.585012988655462"/>
<DICH_DATA CI_END="5.083931341360057" CI_START="0.7782556319475871" EFFECT_SIZE="1.9891199558720223" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.706199676762024" LOG_CI_START="-0.10887772780585922" LOG_EFFECT_SIZE="0.29866097447808243" ORDER="4" O_E="3.0" SE="0.478780502141398" STUDY_ID="STD-Crook-1996" TOTAL_1="75" TOTAL_2="75" VAR="4.3624161073825505" WEIGHT="11.950015806869935"/>
<DICH_DATA CI_END="0.8960656017683439" CI_START="0.10111739513077608" EFFECT_SIZE="0.3010113278883475" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.047660194084456986" LOG_CI_START="-0.9951741267090525" LOG_EFFECT_SIZE="-0.5214171603967548" ORDER="5" O_E="-3.8757396449704142" SE="0.5565743742932976" STUDY_ID="STD-GCISN-1985" TOTAL_1="83" TOTAL_2="86" VAR="3.228149107757665" WEIGHT="8.842905379739907"/>
<DICH_DATA CI_END="2.206820660987368" CI_START="0.4210102151054825" EFFECT_SIZE="0.9638952438836467" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.34376704131379754" LOG_CI_START="-0.3757073666105972" LOG_EFFECT_SIZE="-0.01597016264839988" ORDER="6" O_E="-0.20588235294117574" SE="0.4226228286705471" STUDY_ID="STD-Herrmann-1997" TOTAL_1="69" TOTAL_2="67" VAR="5.59878892733564" WEIGHT="15.336825863026771"/>
<DICH_DATA CI_END="20.466211589870753" CI_START="0.5713299541248599" EFFECT_SIZE="3.4194969993773254" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.311037459766526" LOG_CI_START="-0.24311300581848067" LOG_EFFECT_SIZE="0.5339622269740226" ORDER="8" O_E="1.4752475247524752" SE="0.9129156766535114" STUDY_ID="STD-Nappi-1997" TOTAL_1="51" TOTAL_2="50" VAR="1.199882364474071" WEIGHT="3.2868513385470672"/>
<DICH_DATA CI_END="3.000282336747954" CI_START="0.8054565630580381" EFFECT_SIZE="1.5545408000952392" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="20" LOG_CI_END="0.47716212522704315" LOG_CI_START="-0.09395787539728861" LOG_EFFECT_SIZE="0.1916021249148773" ORDER="9" O_E="3.9200000000000017" SE="0.3354787154563303" STUDY_ID="STD-Roelandts-1994" TOTAL_1="96" TOTAL_2="104" VAR="8.885258291457285" WEIGHT="24.339488580960722"/>
<DICH_DATA CI_END="4.400693174383839" CI_START="0.11306778575835275" EFFECT_SIZE="0.7053911206057795" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6435210896905921" LOG_CI_START="-0.9466611126714942" LOG_EFFECT_SIZE="-0.15157001149045107" ORDER="10" O_E="-0.3999999999999999" SE="0.9340808971963416" STUDY_ID="STD-Saletu-1995" TOTAL_1="24" TOTAL_2="26" VAR="1.1461224489795918" WEIGHT="3.139586193700424"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>